LifeStance Health Group (LFST) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this outpatient mental health services provider would post a loss of $0.09 per share when it actually produced a loss of $0.06, delivering a surprise of 33.33%. Over the ...

Exhibit 99.1 Investor Relations Contact Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Second Quarter 2024 Results SCOTTSDALE, Ariz. – August 8, 2024 – LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial results for the second quarter ended June 30, 2024. (All results compared to prior-year comparative period, unless otherwise noted) Q2 2024 Highlig ...

Shares of LifeStance Health Group (LFST) have gained 13.7% over the past four weeks to close the last trading session at $5.58, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $8.64 indicates a potential upside of 54.8%. The mean estimate comprises seven short-term price targets with a standard deviation of $0.94. While the lowest estimate of $7 indicates a 25.5% increase from t ...

Core Insights - Lifeist Wellness Inc. is launching a new product called FOCUS, developed by its U.S. biosciences subsidiary Mikra Cellular Sciences Inc., in collaboration with former MLB player Jose Bautista [2][12] - FOCUS is designed to enhance memory, concentration, and cognition using a blend of citicoline, tyrosine, and lion's mane mushroom, without caffeine or stimulants [2][4][6] - The product is set to be launched in late September 2024, with a comprehensive marketing plan in place [2][12] Company Overview - Lifeist Wellness Inc. focuses on health-tech innovations that transform human wellness through scientific advancements [2][18] - The company operates multiple business units, including Mikra, which specializes in biosciences and consumer wellness products, and CannMart, which deals with cannabis distribution [18] Product Development - The development of FOCUS involved extensive third-party clinical research to determine the optimal formula for cognitive enhancement [2][6] - The active ingredients in FOCUS have been clinically studied and shown to support improved cognitive functions [6][13] Market Strategy - The marketing plan for FOCUS is being developed with insights and resources provided by Jose Bautista, emphasizing the importance of market research and strategic planning [3][12] - Lifeist aims to reach a broader customer base in 2024 and beyond, leveraging the growing nutraceutical market, which is expected to remain a multi-billion dollar industry [16][18]

LifeStance Health Group (LFST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street anal ...

TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF) a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced that it has closed a non-brokered private placement (the "Offering") of secured convertible debentures (the "Debentures") for aggregate gross proceeds to the Company of $450,000 ("Principal Amount"). The Company inte ...

SCOTTSDALE, Ariz., July 18, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental health care, will issue its second quarter 2024 earnings release before the market opens on Thursday, August 8, 2024. LifeStance will host a live earnings conference call to discuss second quarter results on August 8, 2024, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationall ...

TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") has unveiled its Big Summer Sale, with a free gift included with every order while supplies last. The sale is on now, and customers are invited to ...

The mean estimate comprises seven short-term price targets with a standard deviation of $0.94. While the lowest estimate of $7 indicates a 27.5% increase from the current price level, the most optimistic analyst expects the stock to surge 82.2% to reach $10. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. However, an impressive consensus price target is not the only ...

CELLF 2.0 provides a complete adult daily dose of Pyrroloquinoline Quinone (PQQ) and Glutathione, alongside the recommended dose of bioavailable CoQ10, in a liposomal gel that is precision engineered to protect all of these key molecules from the corrosive effects of stomach acid, delivering them safely to be absorbed by the small intestine and guaranteeing that the full clinical dose becomes bioavailable. The latest published research confirms the vital role played by CELLF 2.0's key ingredients. In 2023 a ...